Trial of ATYR1923 in Pulmonary Sarcoidosis Patients Nears Finish

Trial of ATYR1923 in Pulmonary Sarcoidosis Patients Nears Finish

299777

Trial of ATYR1923 in Pulmonary Sarcoidosis Patients Nears Finish

A Phase 1/2 clinical trial testing ATYR1923 in people with pulmonary sarcoidosis has now finished all required patient visits. Results from this proof-of-concept study are expected this September. “We are pleased to complete the last patient visit in this important study, which represents a significant milestone for aTyr, our ATYR1923 clinical program and the sarcoidosis community,” Sanjay Shukla, MD, president and CEO of aTyr Pharma, which is developing the candidate therapy, said in a press release. “We would like to…

You must be logged in to read/download the full post.